By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –Response Biomedical said on Wednesday that it has closed on a previously announced C$8 million ($7.7 million) private placement.

More than 13.3 million shares in aggregate were placed to Caduceus Private Investments III, OrbiMed Associates III, and Caduceus Asia Partners, all affiliates of OrbiMed Advisors. Each share was priced at C$0.60.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.